Focus on HIV Care

Back to articles

Increased cardiovascular risk with abacavir: When and why


According to a recent study, the risk of cardiovascular disease (CVD) events with abacavir (Ziagen—GlaxoSmithKline) is not immediate but increases in a cumulative manner with recent years of use. This finding has implications for the mechanism of abacavir-associated CVD events.